Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
October 31 2013 - 11:35AM
Marketwired
Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General
Biotechnology for Contract Manufacturing of HemaXellerate I
SAN DIEGO, CA--(Marketwired - Oct 31, 2013) - Bio-Matrix
Scientific Group, Inc. (OTCQB: BMSN) announced today that Regen
BioPharma Inc. (a subsidiary of BMSN) is initiating the production
of clinical-grade HemaXellerate I using the Good Manufacturing
Practices (GMP)-compliant contract manufacturer Cook General
Biotechnology. The initial batches will be utilized for completing
preclinical experiments requested by the FDA for IND # #15376 for a
clinical trial using HemaXellerate I as a therapeutic for treatment
resistant aplastic anemia. HemaXellerate I is a personalized stem
cell treatment that utilizes fat derived cells to inhibit the
biological processes responsible for aplastic anemia.
"We are excited to work with the team at Regen BioPharma in
producing clinical grade HemaXellerate I, initially for preclinical
studies, and subsequently for the clinical trial itself," said Erik
J Woods, Ph.D., CEO of Cook General Biotechnology.
Cook General Biotechnology is dedicated to advancing the science
and practical application of processing, storage, and manufacturing
of cells and tissues to empower new cell-based medical
therapies.
"Dr. Woods and the team at Cook General Biotechnology have
previously guided cell therapy companies from preclinical to
clinical stages in a variety of therapeutic areas. We are
enthusiastic to work with this team at bringing HemaXellerate I to
patients as quickly as possible," said David Koos, Chairman &
CEO of Regen BioPharma, Inc.
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology
company focused on identifying undervalued regenerative medicine
applications in the stem cell space and rapidly advancing these
technologies through pre-clinical and Phase I/ II clinical trials.
For more information refer to the company's website
http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to
which forward looking statements are subject include, but are not
limited to, the effect of government regulation, competition and
other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen BioPharma
Inc. David R. Koos, PhD Chairman & Chief Executive Officer
619-702-1404 www.regenbiopharma.com